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Abstract
Background: One of the most challenging conditions in Crohn’s disease (CD) patients is the treatment of perianal fistulae.
We have recently shown that epithelial-to-mesenchymal transition (EMT) plays a crucial role during CD-fistulae
development. Dickkopf-homolog 1 (DKK-1) is known to play a key role during EMT. Here, we investigated a role for
DKK-1 in the pathogenesis of CD-associated fistulae.
Methods: Dkk-1 protein expression in CD-fistula specimens were investigated by immunohistochemistry. Colonic lamina
propria fibroblasts (CLPF) were obtained from either non-IBD control patients or patients with fistulizing CD. HT-29 intestinal
epithelial cells (IEC) were either grown as monolayers or spheroids. Cells were treated with either TNF-a, TGF-b or IL-13.
Knock-down of DKK-1 or b-Catenin was induced in HT-29-IEC by siRNA technique. mRNA expression was determined by
real-time-PCR.
Results: Dkk-1 protein was specifically expressed in transitional cells lining the fistula tracts. TGF-b induced DKK-1 mRNA
expression in HT-29-IEC, but decreased it in fistula CLPF. On a functional level, DKK-1 knock-down prevented TGF-b-induced
IL-13 mRNA expression in HT-29-IEC. Further, loss of b-Catenin was accompanied by reduced levels of DKK-1 and, again, IL-
13 in IEC in response to TGF-b. In turn, treatment of HT-29-IEC as well as fistula CLPF with IL-13 resulted in decreased levels
of DKK-1 mRNA. Treatment with TNF-a or the bacterial wall component, muramyl-dipeptide, decreased DKK-1 mRNA levels
in HT-29-IEC, but enhanced it in fistula CLPF.
Discussion: We demonstrate that DKK-1 is strongly expressed in cells lining the CD-fistula tracts and regulates factors
involved in EMT initiation. These data provide evidence for a role of DKK-1 in the pathogenesis of CD-associated perianal
fistulae.
Citation: Frei SM, Hemsley C, Pesch T, Lang S, Weber A, et al. (2013) The Role for Dickkopf-Homolog-1 in the Pathogenesis of Crohn’s Disease-Associated
Fistulae. PLoS ONE 8(11): e78882. doi:10.1371/journal.pone.0078882
Editor: Jun Sun, Rush University Medical Center, United States of America
Received April 26, 2013; Accepted September 17, 2013; Published November 8, 2013
Copyright:  2013 Frei et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a grant from Fonds zur Fo¨rderung des akademischen Nachwuchses (FAN) of the Zu¨rcher Universita¨tsverein (ZUNIV) to
MS, a research grant from the Swiss Philanthropy Foundation to MS and GR, a research credit from the University of Zurich to MS, research grants from the Swiss
National Science Foundation (SNF) to MS (grant number 314730–146204), GR (grant number 310030–120312) and the Swiss IBD Cohort (grant number 3347CO-
108792) and by research grants from the Zurich Center for Integrative Human Physiology (ZIHP) of the University of Zurich to MS and GR. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: michael.scharl@usz.ch
Introduction
Perianal and intestinal fistulae represent a frequent complica-
tion in up to 50% of patients with Crohn’s disease (CD) [1–3], one
of the major types of inflammatory bowel diseases (IBD), and pose
a challenging problem, since current treatment options such as
administration of antibiotics [4], immunosuppressants or tumor
necrosis factor alpha (TNF-a) antibodies often are insufficient to
cure the complication and achieve complete fistula closure [5–8].
Surgical intervention is frequently required, however, often not
providing a definitive cure.
So far, the pathogenesis of fistula formation in CD is poorly
understood. A better knowledge is essential to improve and
develop targeted therapeutic strategies. In morphological studies,
we have recently demonstrated that some remaining epithelial cells
are present on the inner surface of fistula tracts while other cells
show mesenchymal or myofibroblast-like features. The latter have
been categorized as so-called ‘‘transitional cells’’ (TC) [9]. Our
previous data demonstrate that in CD fistulae the polarized
epithelial cells are undergoing transformation into TC, a process
known as epithelial-mesenchymal transition (EMT) [10–11].
These TCs express both, mesenchymal markers, like increased
levels of vimentin and a-SMA, but coincidentally also typical
epithelial cell markers such as cytokeratine-8 and -20 [11–14].
EMT plays a crucial role in physiological processes such as
embryogenesis, organ development, wound repair and tissue
remodeling, but is also involved in pathological processes like
tissue fibrosis or cancer progression [15–17]. The most powerful
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Figure 1. Dkk-1 is strongly expressed in TCs lining the fistula tract of CD patients. Immunohistochemical stainings of healthy control
subjects (Co, A), fistula tissue derived from CD-patients (fistCD, B), CD-patients with active disease (aCD, C), patients with an active ulcerative colitis
(aUC, D), CD patients in remission (remCD, E) and colitis patients in remission (remUC, F) were analyzed. The representative section of the fistula
associated to CD highlights the presence of Dkk-1 in TCs lining the fistula tract (red arrow), cells covering the fistula tract (black arrows), whereas
surrounding cells show almost no staining signal (white arrows). Asterisks indicate the fistula tract. Pictures are acquired with a 10-fold magnification.
doi:10.1371/journal.pone.0078882.g001
Figure 2. TGF-b induces mRNA expression of DKK-1 in human IEC, but reduces it in control and CD-derived fistula fibroblasts. DKK-1
mRNA expression is demonstrated in (A) HT-29 cells treated with TGF-b (50 ng/ml) for 24 h (n = 3), (B) HT-29 spheroids treated with TGF-b for 1, 3, 5 or
7 days, fibroblasts of (C) non-IBD-control patients (n = 3) and (D) CD-associated fistulae (n = 3), both treated with TGF-b for 24 h. Asterisks indicate
significant differences versus the respective control. * = p,0.05, ** = p,0.01.
doi:10.1371/journal.pone.0078882.g002
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inducer of EMT is tumor growth factor beta (TGF-b) [18–19].
TGF-b causes the epithelial cells to lose polarity and cell-cell
interactions, characterized by down-regulation of E-Cadherin
mediated by its repressor Snail1 [20–21]. Additionally, TGF-b
induces b-Catenin translocation into the nucleus to regulate target
gene expression. Notably, TGF-b can be induced by TNF-a [22].
Although TGF-b is the most powerful EMT inducer, Bates et al.
showed that also TNF-a is able to induce EMT in colonic
organoids [23].
Recently we demonstrated that TC up-regulate expression of
genes associated with cell migration and invasion, such as
SNAIL1, SLUG (SNAIL2) and b6-integrin [11,12]. Further, we
detected strong expression of interleukin-13 (IL-13) in TC lining
the tracts of CD-associated perianal fistulae and revealed that IL-
13 secretion can be induced by TGF-b in fibroblasts derived from
fistulizing CD-patients. IL-13 then causes an increased expression
of b6-integrin and the transcription factor SLUG in HT-29 cells
[12]. We also found that SNAIL1 levels in TGF-b- as well as
SLUG and b6-integrin levels in IL-13-exposed IEC are clearly
increased, providing a further hint to the onset of EMT [12].
An important factor involved in the regulation of cell migration
is Dickkopf-homolog-1 (DKK-1). Loss of DKK-1 has been
associated with progression of certain types of cancers, such as
colorectal carcinoma (CRC) [24–26,28]. On a functional level, the
secreted glycoprotein is capable to block IEC migration [27–28].
Additionally, DKK-1 is a potent antagonist of the canonical Wnt/
b-Catenin signaling pathway and has been implicated to act as a
mediator of inflammation [27]. Wnt pathway regulates Dkk-1
expression through b-Catenin/T-cell factor (TCF), in particular
TCF-4 [28].
Here, we show that TNF-a, TGF-b and IL-13 are involved in
regulatory feedback loops likely controlling cell migration and
invasion in the pathogenesis of CD-associated perianal fistulae.
Unfortunately, since there is no well-established animal model
available for studying fistula development in CD, our data are
limited to the presented ex vivo and in vitro approaches. Neverthe-
less, our data demonstrate for the first time that TGF-b-stimulated
IL-13 secretion might be regulated via DKK-1, strongly suggesting
an involvement of DKK-1 in the pathogenesis of CD-associated
perianal fistulae.
Materials and Methods
Cell Lines
HT-29-IECs of human origin were either grown as monolayers
or spheroids in a humidified atmosphere with 10% CO2 at 37uC
in low glucose Dulbecco’s modified Eagle’s medium (Invitrogen,
Carlsbad, CA) containing 1000 mg/L D-glucose, L-glutamine and
Figure 3. Knock-down of DKK-1 prevents TGF-b induced up-regulation of IL-13. (A) DKK-1 expression in control-transfected cells and after
DKK-1-siRNA transfection with or without TGF-b (50 ng/ml) treatment (n = 5). (B) IL-13 (n = 4), (C) b6-Integrin (n = 5) and (D) SLUG mRNA expression
(n = 4) in HT-29-IEC in control-transfected and transfected cells with or without application of TGF-b for 24 h. Asterisks indicate significant differences
versus the respective control whereas # indicates significant differences versus TGF-b treatment and u indicates significance in comparison to non-
treated siRNA transfected cells. */#=p,0.05, **/##=p,0.01, ***/###/uuu=p,0.001.
doi:10.1371/journal.pone.0078882.g003
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sodium pyruvate which was additionally supplemented with 1%
penicillin/streptomycin solution (Invitrogen) and 5% fetal calf
serum (FCS; VWR).
Patient Samples
Both genders were included in our studies. Tissue samples from
healthy control subjects, patients with active ulcerative colitis
(n = 3), ulcerative colitis in remission (n= 3), active Crohn’s disease
(n = 5), Crohn’s disease in remission (n= 4) and perianal fistula
specimens from CD-patients (n = 8) were used for immunohisto-
chemical stainings. These specimens were surgically resected,
transferred into 4% formalin and stored at 4uC until further
analyses were performed. Intestinal fibroblasts of non-IBD-
subjects and fistulizing CD-patients were cultivated using men-
tioned surgical specimens. The procedure of fibroblast isolation is
described below.
Written informed consent was obtained and the studies were
approved by the Cantonal Ethics Committee Zu¨rich (Approval no.
EK-1755) before specimens were collected. All investigations have
been conducted according to the principles expressed in the
Declaration of Helsinki.
Isolation and Culture of Human Colonic Lamina Propria
Fibroblasts (CLPF)
Primary CLPF cultures were obtained from seven fistulizing
CD-patients (mean age 5365 yrs). Fistula tracts of surgical
specimens were initially cut into pieces of 1 mm thickness and
rinsed in fibroblast medium consisting of high glucose Dulbecco’s
modified Eagle’s medium (DMEM; PAA, Co¨lbe, Germany)
supplemented with 10% FCS (Gibco, Karlsruhe, Germany) and
cultured in 25 cm2 culture flasks (Costar, Bodenheim, Germany)
with DMEM containing 10% FCS, penicillin (100 IU/ml),
streptomycin (100 mg/ml), ciprofloxacin (8 mg/ml; Bayer), genta-
mycin (50 mg/ml; Invitrogen) and amphotericin B (1 mg/ml;
Roth). The tissue was washed and digested for 30 min at 37uC in
phosphate buffered saline (PBS, Gibco) containing calcium and
magnesium ions (PAA), 1 mg/ml collagenase I (Sigma, St. Louis,
MO), 0.3 mg/ml DNase I (Boehringer, Mannheim, Germany)
and 2 mg/ml hyaluronidase (Sigma). Thereafter, the isolated cells
were rinsed again. The tissue pieces from the fistula were put onto
scratched petri dishes containing fibroblast medium until fibroblast
migration was reached. Cells were further grown in a humidified
atmosphere with 10% CO2 at 37uC in high glucose Dulbecco’s
modified Eagle’s medium containing 10% FCS, an antibiotic
agent (alternately ciprofloxacin, 8 mg/ml or gentamycin, 50 mg/
ml), 1% non-essential amino acid solution (NEAA), 1% sodium
pyruvate (Sigma-Aldrich), 1% vitamin solution and 1% L-
glutamine (Sigma).
The same procedure was performed for isolation of intestinal
control fibroblasts deriving from six non-IBD subjects (mean age
49612 yrs).
Immunohistochemistry
Immunohistochemical studies were performed using a peroxide
based method on tissue specimens fixed in formalin and embedded
in paraffin. The tissue samples were first deparaffinized with
HistoclearH (Brunschwig), descending concentrations of ethanol,
and rehydrated. Antigen retrieval was performed using citrate
buffer, pH 6.0 (DAKO, Glostrup, Denmark) for 45 min at 98uC
in a water bath and cooled down to room temperature (RT).
Thereafter, tissues were washed in PBS. Endogenous peroxidases
were eliminated by incubation with 0.9% hydrogen peroxide for
15 min at RT. The specimens were washed in PBS and blocked
with 1% BSA in PBS in a wet chamber for 1 h at RT, mouse-anti-
DKK-1-antibody (1 mg/ml; Abnova) added, incubated for 3 h at
Figure 4. IL-13 levels are decreased in b-Catenin knock-down-cells compared to b-Catenin-competent cells. (A) mRNA expression and
(B) protein levels of b-Catenin (n = 2), mRNA levels of (C) DKK-1, (D) IL-13 and (E)TCF-4 in control and b-Catenin-knock-down HT-29 IEC stimulated with
or without TGF-b (50 ng/ml) for 24 h (n = 5 each experiment).Asterisks indicate significant difference versus the no stimulated control cells whereas#
indicates significant differences versus TGF-b treated control cells. */#=p,0.05, **/##=p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0078882.g004
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RT and rinsed with PBS. Secondary antibody (EnVisionTM
System anti-mouse-HRP-labeled polymer from DAKO) was
applied for 3 h at RT. To visualize the antibody binding, DAB
method was used according to manufacturer’s instructions
(DAKO). The samples were counterstained with hematoxyline
and dehydrated in ascending concentrations of ethanol and
HistoclearH and finally mounted in PertexTM. Microscopic
assessment were performed using an AxioCam MRc5 (Zeiss,
Jena, Germany) on a Zeiss Axiophot microscope (Zeiss) with Axio
Vision Release 4.7.2 software (Zeiss).
Western Blotting
HT-29 whole cell lysates obtained using mammalian protein
extraction reagent (MPER; Thermo Scientific) were mixed with an
equal amount of 26gel loading buffer (50 mmol/L Tris, pH 6.8,
2% sodium dodecyl sulfate, 200 mmol/L dithiothreitol, 40%
glycerol, 0.2% bromophenol blue) and heated up to 95uC for 10
minutes. By sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, proteins were separated and transferred onto nitrocellu-
lose membranes (Brunschwig). Membranes were blocked with a
blocking solution containing 3% milk and 1% BSA. The
membranes were incubated over night at 4uC with an anti-Dkk-
1 monoclonal antibody (Novus Biologicals; dilution of 1:1000), an
anti-b-Catenin polyclonal antibody (Cell Signaling; dilution of
1:1000; produced in rabbit) or an anti-b-Actin monoclonal
antibody (Sigma; dilution of 1:3000, produced in mouse).
Membranes were washed 3 times with tris-buffered saline
containing 0.1% tween 20 (0.1% TBST) for 10 minutes,
horseradish-peroxidase–labeled secondary anti-mouse- or anti-
rabbit–IgG-antibody (Santa Cruz Biotechnology) in the mentioned
blocking solution was added for 1 hour at RT and membranes
were washed 3 times for 10 minutes with TBST. Proteins were
detected using an enhanced chemiluminescence detection kit (GE
Healthcare).
Stimulation of HT-29-IEC
HT-29 were re-suspended in 500 ml HT-29 medium and seeded
onto inserts in 24 well plates. 500 ml HT-29 medium was added
Figure 5. IL-13-induced decrease of DKK-1 mRNA expression is reversed by an anti-IL-13 antibody in IEC and in fibroblasts. (A) DKK-
1 mRNA expression in HT-29 cells stimulated with IL-13 (100 ng/ml) for 30 min, 24 h and 72 h (n = 3). (B) Effect on DKK-1 levels in HT-29-IEC treated for
24 h alone with IL-13, an anti-IL-13 antibody (100 mg/ml) or a combination of both (n = 12). (C) Expression pattern of DKK-1 in HT-29-spheroids
exposed to IL-13 for 1, 5 and 7 days (n = 3). (D) DKK-1 mRNA expression in intestinal control fibroblasts (n = 5) and (E) in CD- patients with a fistulizing
course (n = 4). Asterisks indicate significant differences versus the respective control whereas # indicates significant differences versus IL-13
treatment. */#=p,0.05, ##=p,0.01, ***/###=p,0.001.
doi:10.1371/journal.pone.0078882.g005
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outside the inserts. Cells were grown for five days, medium
removed and replaced by low glucose DMEM without additives.
After starvation, HT-29 cells were basolaterally stimulated with
either 100 ng/ml human recombinant Interleukin-13 (rhIL-13,
R&D), 100 mg/ml of an anti-IL-13 antibody (provided by Novartis
AG, Basel, Switzerland), 50 ng/ml human recombinant tumor
necrosis factor alpha (TNF-a, Calbiochem/Merck, VWR), 50 ng/
ml human recombinant tumor growth factor beta (TGF-b1,
Calbiochem/Merck, VWR), 100 ng/ml muramyl dipeptide
(MDP, InvivoGen) in a dimethyl sulfoxide (DMSO) – FuGene
transfection reagent (Promega) solution, 100 ng/ml ultra-pure
lipopolysaccharide (LPS, from E. coli, InvivoGen) and/or 24 mg/
ml of an anti-TNF-antibody. The concentrations used for IL-13,
anti-IL-13 antibody, TNF-a and TGF-b for the stimulation of the
cells were adopted from Scharl M. et al. [12].
Stimulation of Human CLPF
Primary fibroblasts re-suspended in 2 ml fibroblast medium of
healthy control and fistulizing CD-patients were seeded into six
well plates and grown until high grade confluence. Medium was
replaced by DMEM without additives. Stimulation was performed
as described above.
Spheroids as in-vitro Model for EMT
HT-29-IECs were used for cultivation of spheroids as three-
dimensional cell culture model for EMT [12]. 4.56103 cells per
spheroid were re-suspended in 24 ml HT-29 medium. Spheroids
were then seeded in Terasaki plates (GREINER–Microtest-Plates,
TC; EBIS/Huber & Co) with 60 cavities and grown for seven
days. At day seven after seeding, spheroids were stimulated with
either 1 ml HT-29 medium, 50 ng/ml TGF-b or 100 ng/ml IL-13
Figure 6. TNF-a inhibits DKK-1 mRNA expression in human IEC. (A) DKK-1 mRNA expression in response to TNF-a (50 ng/ml) and/or an anti-
TNF-a antibody (24 mg/ml) for 24 h in HT-29-IEC (n = 3 for each experiment). (B) Control CLPF from healthy individuals (n = 3 for each experiment) and
(C) CD CLPF (n = 4 for each experiment) in response to TNF-a (50 ng/ml) and/or an anti-TNF-a antibody (24 mg/ml) for 24 h. Asterisks indicate the
difference versus the respective untreated control whereas# indicates significant differences versus TNF-a-treated cells. * = p,0.05, **/##=p,0.01,
*** = p,0.001.
doi:10.1371/journal.pone.0078882.g006
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in 1 ml HT-29 medium. Spheroids were harvested at different time
points.
Real-time Polymerase Chain Reaction (RT-PCR)
Cells were lyzed in RLT-buffer (Qiagen, Valencia, CA)
containing 1% b-mercaptoethanol. RNA was isolated using
RNeasy Plus Mini Kit (Qiagen, Valencia, CA) using a QIA-Cube
(Qiagen) and DNA was removed by DNase I (Qiagen) according
to manufacturer’s instructions. RNA concentration was deter-
mined by absorbance at 230 nm using NanoDrop ND1000
(Thermo Scientific). cDNA synthesis was performed using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). TaqMan Assays and TaqMan Gene Expression
Master Mix were obtained from Applied Biosystems. RT–PCR
was performed in a 7900HT Fast RT–PCR system using SDS 2.2
software (Applied Biosystems). Conditions were set on 45 cycles,
an enzyme activation of 20 s at 95uC, 1 s denaturation at 95uC
and the anneal/extend at 60uC for again 20 s. Triplicate
measurements were performed. Results were analyzed with
nnCT-method. Measured values were normalized to endoge-
nously expressed b-Actin.
Small Interfering RNA (siRNA) Transfection
A transient knock-down of b-Catenin or DKK-1 was reached
using siRNA constructs specific either for b-Catenin or DKK-1
(both from Applied Biosystems) in HT-29-IEC. 16106 IEC were
re-suspended with 100 ml MirusH IngenioTM Electroporation
Solution (Mirus Bio LLC, Madison, WI) either without specific
siRNA constructs, serving as control, or with 5 nmol standard
purity of three different annealed b-Catenin- or DKK-1-specific
SilencerH Pre-designed siRNA oligonucleotides. Cell transfection
was performed using the Amaxa nucleofector system (Lonza,
Walkersville, MD). Transfected cells were cultured on filter
membranes for two days before they were stimulated with either
TNF-a, TGF-b or IL-13. Medium was changed 24 h after
transfection to remove the remaining electroporation reagent.
Statistical Analysis
Data are shown as means +/2 S.D. for a series of n
experiments. Statistical analyses were performed with InStat3TM
software (GraphPad software Inc.) by one way ANOVA followed
by Student-Newman-Keuls post hoc test. P-values ,0.05 were
considered significant.
Figure 7. DKK-1 expression is decreased in IEC when MDP is present. DKK-1 mRNA expression in (A) HT-29-IEC (n = 3), (B) in control CLPF
(n = 3) and (C) in CD CLPF (n = 4) in response to MDP (100 ng/ml) or LPS (100 ng/ml) for an exposition of 24 h. Asterisks indicate the difference versus
the respective untreated control. ** = p,0.01.
doi:10.1371/journal.pone.0078882.g007
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Results
Dkk-1 is Expressed along Fistula Tracts in CD
Dkk-1 has been associated with an altered migratory potential of
epithelial cells. Since we recently found that genes involved in cell
migration and invasion are expressed along or around the tracts of
CD-associated perianal fistulae [11–12], we assessed whether Dkk-
1 would be present in fistula specimens of CD-patients. In
immunohistochemically stained intestinal tissue samples derived
from non-IBD control patients, Dkk-1 staining was very weak
(Figure 1, A). In tissue samples from CD-patients with a perianal
fistula (n = 9) Dkk-1 staining was detectable in TCs lining the
fistula tracts (Figure 1, B, red arrow). Dkk-1 also was detected in
the fibrotic areas adjacent to the fistula tracts (Figure 1, B, black
arrow), while fistula surrounding areas consisting of inflammatory
cells almost were free of Dkk-1 staining (Figure 1, B, white arrow).
In acute inflamed intestinal tissue during active CD (Figure 1,
C) and UC (Figure 1, D), we found a strong staining signal for
Dkk-1, representing a high cell turnover and, likely, ongoing
wound repair mechanisms. In contrast, Dkk-1 staining was weak
in IEC of regular colonic crypts in patients with CD (Figure 1, E)
and UC (Figure 1, F) in remission comparable to healthy control
tissue (Figure 1, A). In the positive control, human uterus, strong
Dkk-1 staining was detectable (Figures S1, A–B), whereas the
negative control revealed no unspecific staining in a perianal
fistula (Figures S1, C–D).
On mRNA level, we detected increased levels of DKK-1
mRNA in the respective intestinal tissue samples from patients
with active CD and UC when compared to samples from non-IBD
control patients or patients with CD in remission fully supporting
our observations by IHC (data not shown). These data demon-
strate that Dkk-1 protein is highly expressed in TCs lining the
tracts of CD-associated fistulae and suggest that Dkk-1 might be
relevant during fistula pathogenesis.
TGF-b Induces DKK-1 mRNA Expression in IEC, but
Decreases it in CD Fistula CLPF
TGF-b is the most important trigger of EMT [18–19,22].
Therefore, we assessed the effect of TGF-b on DKK-1 expression
in IEC and CLPF. Application of 50 ng/ml TGF-b significantly
increased DKK-1 mRNA expression in HT-29 monolayers after
treatment for 24 h (Figure 2, A). Of note, protein levels of Dkk-1
were also increased after a treatment of HT-29 cells treated with
TGF-b for 24 h (Figure S2, A). Correspondingly, in the HT-29-
spheroid cell EMT-model DKK-1 mRNA was already increased
upon TGF-b stimulation after 1 day and this effect reached
statistical significance after treatment for 7 days (Figure 2, B). In
contrast, in both, control and CD CLPF, TGF-b significantly
Figure 8. DKK-1 regulates TGF-b induced IL-13 secretion in CD-associated perianal fistulae. Under chronic inflammatory conditions, TNF-
a, and also IL-13, are present at high levels and exert inhibitory effects on DKK-1 mRNA expression in IEC. TNF-a further stimulates TGF-b secretion
that promotes DKK-1 mRNA expression in IEC. The effects of the cytokine and the growth factor on DKK-1 are mediated via b-catenin/TCF. On a
functional level, TGF-b induces IL-13 secretion via a b-catenin/DKK-1-dependent pathway. These mechanisms through synergism between TGF-b and
IL-13 finally lead to an enhanced expression of genes associated with EMT and therefore to the formation of perianal fistulae associated to CD.
doi:10.1371/journal.pone.0078882.g008
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down-regulated DKK-1 mRNA expression by treatment for 24 h
(Figure 2, C–D). These findings demonstrate that TGF-b exerts
different effects on DKK-1 expression in IEC and CLPF. While
the growth factor increases DKK-1 mRNA in IEC, it reduces
DKK-1 mRNA in CLPF derived from healthy non-IBD-subjects
and CD-patients with a fistulizing disease course.
TGF-b Induces IL-13 via DKK-1
We next studied the impact of DKK-1 on the expression of
genes involved in fistula pathogenesis. Therefore, we transfected
HT-29-IEC either with unspecific control siRNA constructs or
with DKK-1 specific siRNA constructs and treated the cells with
TGF-b (24 h, 50 ng/ml). As expected, presence of DKK-1-specific
siRNA constructs clearly reduced DKK-1 basal mRNA levels and
TGF-b was no longer able to induce DKK-1, implying a successful
DKK-1 knock-down on mRNA level (Figure 3, A) as well as on
protein level (Figure S2, B). Subsequently we assessed the
expression pattern of IL-13, b6-integrin and the transcription
factor SLUG in response to the growth factor (Figure 3, B–D). As
expected, TGF-b induced IL-13 mRNA in DKK-1 competent
cells. Of note, this effect was absent in DKK-1 knock-down cells
(Figure 3, B). However, DKK-1 depletion had no significant effect
on TGF-b induced up-regulation of b6-integrin (Figure 3, C) or on
the expression of the transcription factor SLUG (Figure 3, D).
These findings strongly suggest that TGF-b induces IL-13, but not
b6-integrin expression in IEC via DKK-1.
b-Catenin Regulates DKK-1 mRNA Expression in HT-29-
IEC
Along with DKK-1, b-catenin plays a major role in the Wnt-
signaling pathway. Hereby, b-catenin seems to be upstream of
DKK-1 [28]. Therefore, we studied whether knock-down of b-
catenin would alter TGF-b-induced increase in DKK-1 mRNA
levels. We transfected HT-29-IEC with either non-specific or b-
catenin-specific siRNA constructs. As shown in figure 4, b-catenin
siRNA decreased b-catenin mRNA levels (Figure 4, A) as well as
protein levels (Figure 4, B) significantly. Of note, the TGF-b
induced increased in DKK-1 mRNA was ameliorated in b-catenin
deficient cells (Figure 4, C). Surprisingly basal levels of DKK-1
mRNA were already elevated in untreated b-catenin deficient cells
(Figure 4, C). Further, we found that untreated as well as TGF-b -
treated b-catenin deficient cells express significantly less IL-13
mRNA compared to b-catenin competent IEC (Figure 4, D).
Interestingly, TGF-b treatment decreased levels of TCF-4
transcription factor that interacts with b-catenin to regulate
DKK-1 expression [35]. Further, we found a significant reduction
of TCF-4 in untreated as well as TGF-b -treated cells lacking b-
catenin (Figure 4, E), thus being consistent to the fact that nuclear
complex formation of b-catenin/TCF-4 takes place during
canonical Wnt-signaling pathway [28,35]. These data strongly
suggest that b-catenin regulates Dkk-1 mRNA expression in IEC
in response to TGF-b and is, similar to Dkk-1, involved in the
regulation of TGF-b-induced IL-13 expression in IEC. These
observations could provide a functional role for b-catenin in the
pathogenesis of CD-associated fistulae.
IL-13 Minimizes DKK-1 Levels in Epithelial Cells and
Fibroblasts
We have recently shown that synergisms between TGF-b and
IL-13 might play a role in the pathogenesis of CD-associated
fistulae [12]. Since we have shown that DKK-1 regulates TGF-b-
induced expression of IL-13 in HT-29-IEC, we next investigated
whether IL-13 might be able to regulate the expression of DKK-1
as part of a possible feedback mechanism. We treated HT-29-IEC,
HT-29-spheroids and fibroblasts from either non-IBD control
patients or patients with fistulizing CD with IL-13 (100 ng/ml). In
a first step, we assessed different time points to evaluate the
maximal alteration in gene expression (Figure 5, A). The cytokine
lead to a significant decrease in DKK-1 mRNA expression levels
after 24 and 72 h in HT-29 monolayers. As expected, this down-
regulation could be reversed after 24 h by co-administration of an
anti-IL-13 antibody (100 mg/ml) (Figure 5, B). In HT-29-
spheroids, IL-13 decreased DKK-1 mRNA expression after 24 h
and the IL-13-induced effect on DKK-1 was declining after 5 and
7 d (Figure 5, C). The effects of IL-13 on DKK-1 expression seen
in HT-29-IEC and spheroids could also be detected in control and
CD fistula fibroblasts (Figure 5, D–E). Here, IL-13 caused a down-
regulation of DKK-1 mRNA in both groups. However, while anti-
IL-13 treatment fully reversed this effect in control CLPF, the
antibody had only a limited, but nevertheless significant, effect in
fistula CLPF. The antibody alone had no effect on DKK-1 mRNA
expression in all studied cell types. In summary, IL-13 treatment
reduced levels of DKK-1 mRNA in IEC as well as in CLPF of
healthy and fistulizing individuals. This effect could be reversed by
an anti-IL-13 antibody implying a potential role of the cytokine in
the onset and progression of fistulae.
TNF-a and MDP Induce DKK-1 Expression in CD Fistula
Fibroblasts
Since we have recently shown that TNF-a and TNF-receptor I
are strongly expressed in and around CD-associated fistulae [11],
we next investigated whether TNF-a could also affect DKK-1
mRNA expression in HT-29-IEC as well as in primary CLPF
derived from healthy control subjects or CD-patients with a
fistulizing disease course. In HT-29-IEC, administration of 50 ng/
ml TNF-a for 24 h significantly reduced DKK-1 mRNA
expression by more than 50%, (Figure 6, A). In contrast, treatment
of CLPF of healthy control individuals and fistula fibroblasts with
the cytokine significantly increased DKK-1 expression (Figure 6,
B–C). These effects could be reversed when cells were co-treated
with an anti-TNF-a antibody (Figure 6, A–C).
Since numerous studies strongly suggest an involvement of
bacterial components in CD pathogenesis and since the intracel-
lular receptor for bacterial wall component muramyl dipeptide
(MDP) [29], NOD2, is associated with a fistulizing disease course
in CD [30], we further assessed the effects of MDP, but also the
bacterial component lipopolysaccharide LPS on DKK-1 expres-
sion. Of note, MDP significantly decreased DKK-1 in HT-29 cells
(Figure 7, A), but increased DKK-1 mRNA expression in healthy
control fibroblasts and fistula fibroblasts of CD-patients (Figure 7,
B–C) hereby resembling the effects of TNF-a. LPS had no effect
on the expression of DKK-1 in all three cell types (Figure 7, A–C).
Our data show that TNF-a as well as the bacterial wall
component, MDP, down-regulate DKK-1 mRNA expression in
IEC and TNF-a mediated effects can be neutralized by applying
an anti-TNF-a antibody. In contrast, both stimuli increased DKK-
1 mRNA levels in CLPFs of healthy control individuals and fistula
fibroblasts of CD-patients. These findings suggest divergent
regulatory mechanisms in IEC and CLPF and lead to the
assumption that, besides TNF-a, bacterial components might also
play a role in the pathogenesis of CD-associated fistulae.
Discussion
In the present study we demonstrate increased DKK-1 levels in
cells lining CD-associated perianal fistulae. Since DKK-1, as a
part of the canonical Wnt/b-Catenin pathway, has already been
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shown to be involved in pathological processes such as cell
migration, invasion and notably in EMT [24–26,28,31], this
observation also supports the hypothesis that DKK-1 might be
involved in EMT and consequent fistula formation in CD patients.
TGF-b exerted opposing effects on DKK-1 mRNA expression
in IEC and CLPF. We show that DKK-1 is inducible by TGF-b in
IEC, but it is down-regulated in response to the growth factor in
fistula fibroblasts derived from CD-patients as well as in control
fibroblasts derived from non-IBD control patients. This observa-
tion might be due to the fact that TGF-b induces EMT in IEC.
However, fibroblasts are not capable of undergoing EMT and
therefore, EMT-inducing effects of TGF-b might be altered or
even reversed in these cell types. Of note, DKK-1 is a mediator of
Wnt-signaling, hereby also mediating TGF-b-induced signaling
events. Since TGF-b induces EMT in IEC also via Wnt-related
pathways, it is high likely that DKK-1 represents an important
regulator of TGF-b-induced EMT in IEC. In contrast, in fistula
CLPF, EMT has already taken place. So, the activation of TGF-b-
mediated signaling events that lead to the onset of EMT, are not
necessary anymore and can be turned down, i.e. by the growth
factor itself, resulting, among others, in the TGF-b-induced down-
regulation of DKK-1. The molecular mechanism that IEC and
CLPF feature different DKK-1 expression pattern in response to
TGF-b might be due to epigenetic modifications within the DKK-
1 gene locus.
A further hint to an important role for DKK-1 in the
pathogenesis of CD-associated fistulae is the fact that DKK-1
knock-down prevents the TGF-b-induced up-regulation of IL-13
mRNA expression in IEC. We have previously shown that TGF-b
induced IL-13 expression and secretion might play a crucial role in
the pathogenesis of CD-associated fistulae [12]. Here, we found
that TGF-b was no longer able to induce IL-13 expression in IEC
when DKK-1 was knocked-down. This observation demonstrates
that DKK-1 exhibits a regulatory function with respect to the
TGF-b-mediated expression of IL-13. Further, when b-catenin
was knocked-down, we also found a tendency showing that TGF-
b-induced IL-13 expression is reduced. These findings are
supported by Notani et al. demonstrating that b-catenin is required
to induce IL-13 expression [32], but also by Koch et al. who found
up-regulated b-catenin levels when epithelial cells are damaged
[27], in example during chronic inflammation as observed during
CD. All in all, our data support the hypothesis that TGF-b-
mediated IL-13 stimulation is dependent on b-catenin and DKK-1
in IEC, demonstrating a functional role for both molecules in the
pathogenesis of CD-associated fistulae.
Epithelial cells undergo EMT after being exposed to TGF-b,
simultaneously inducing DKK-1 expression. On a functional level,
elevated Dkk-1 levels in epithelial cells might aim for the inhibition
of Wnt-signaling, meaning limitation of cell proliferation, migra-
tion and invasion. However, as we have shown, DKK-1 seems also
to be required for TGF-b-induced IL-13 expression. These
findings support on one hand the hypothesis that DKK-1 acts as
an antagonist of TGF-b/Wnt-signaling. On the other hand,
DKK-1 seems to be involved in mediating cell invasiveness by
mediating the induction of IL-13 expression. Interestingly, IL-13 is
also up-regulated by TGF-b during EMT and IL-13 actively
suppresses DKK-1 expression. This means that TGF-b induces
DKK-1 as an inhibitor of its own signaling cascades, namely Wnt-
related signaling, but also induces IL-13 via DKK-1. Of note, IL-
13 finally inhibits DKK-1 expression. According to our hypothesis,
in a pathological setting featuring ongoing tissue damage such as
chronic intestinal inflammation, the overwhelming secretion of
TGF-b and the subsequent activation of signaling pathways
associated with cell proliferation, migration and invasion might
finally result in overwhelming secretion of IL-13. IL-13 then
inhibits DKK-1 expression, what, in the end, contributes
essentially to the establishment of EMT. As we have previously
shown, IL-13 then induces genes associated with cell invasion,
such as b6-integrin, thus finally leading to the onset of fistula
formation. Further, fistula fibroblasts that already underwent
EMT, feature a down-regulation of DKK-1 in the presence of
TGF-b, further promoting Wnt-related signaling in these cells,
what might finally lead to an advanced fistula formation.
In our experiments, we also detected decreased levels of DKK-1
in IEC after exposure to TNF-a. Of note, the cytokine had an
opponent effect in perianal fistula fibroblasts derived from CD-
patients. This result is consistent with data shown by Diarra et al.,
suggesting that DKK-1 can be induced by TNF-a in arthritis [33].
Of note, TNF-a can induce EMT in IEC [23] and has also been
well documented to induce secretion of TGF-b [22]. Therefore, it
seems plausible that the TNF-a-induced decrease in DKK-1 levels
plays an essential role for mediating TNF-a-induced EMT, since
down-regulation of DKK-1 obviously promotes the expression of
genes being associated with cell proliferation and migration.
As already mentioned the inflammatory mediator IL-13 blocked
DKK-1 expression not only in HT-29-IEC, but also in fibroblasts
of healthy non-IBD subjects as well as CD associated fistula
patients. This effect could efficiently be reversed in all investigated
cell types by an anti-IL-13 antibody. These findings support our
hypothesis that IL-13 could be an interesting target for fistula
therapy. Notani et al. recently demonstrated that IL-13 expression
is up-regulated via b-catenin [32]. We fully confirm this
observation, since in our b-catenin knock-down experiments, we
observed that IL-13 levels were constantly lower concomitant with
TCF-4 in cells lacking b-catenin compared to b-catenin competent
cells. This finding, in addition to the dual role of b-catenin as an
transcription factor, but also as a part of the intercellular adherens
junctions at the plasma membrane categorizes b-catenin as an
interesting target to investigate in the pathogenesis of fistulae,
where epithelial cells loose intercellular connections [34]. During
EMT, cell-cell contacts are lost mainly seen by a loss of E-
cadherin, but also by lower expression of cytoplasmic or
membrane-bound b-catenin. During EMT, b-catenin instead
translocates into the nucleus in response to TGF-b and forms a
complex with TCF-4 in attempt to regulate target gene
transcription [31]. The reduced b-catenin mRNA levels in IL-
13-treated HT-29-IEC might be due to a negative feedback loop
since b-catenin has already accumulated in the nucleus.
To study EMT in a model, that better resembles the in-vivo
conditions, we analyzed the effects of indicated cytokines not only
in monolayer cells but in three-dimensional multicellular struc-
tures, the aforementioned spheroids. This model is suitable for
studying proliferation, differentiation, migration or cell death
because of the high polarity of epithelial cells and the expression of
junctional proteins [36]. A well-defined geometric structure
enables us to macroscopically assess the spheroids and they
provide us a direct correlation between structure, protein and gene
expression [36] which is not possible in studying monolayer cells.
In summary, we demonstrate that DKK-1 is involved in
regulating processes that are crucially involved in the onset of
EMT in IEC. By regulating DKK-1 expression, TNF-a, TGF-b
and IL-13 appear to be involved in regulatory feedback loops
controlling cell migration and invasion in the pathogenesis of CD-
associated perianal fistulae via DKK-1 (Figure 8). We have further
demonstrated that IL-13 secretion is to be regulated via DKK-1 in
response to TGF-b. The observations that mRNA levels of DKK-
1 are altered in response to the mediators TGF-b, TNF-a and IL-
13, all of them being essentially involved in EMT-associated fistula
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formation, suggest that DKK-1 might also to be an interesting
target in fistula therapy. All in all, our data provide strong
evidence for an involvement of DKK-1 in the pathogenesis of CD-
associated perianal fistulae.
Supporting Information
Figure S1 Control staining against Dkk-1. (A) Positive control
staining against Dkk-1 (black arrow) in human uterus tissue. (C)
Negative control staining using just the secondary antibody in
perianal fistula tissue. (B, D) Representative sections of (A, C). The
white arrow indicates Dkk-1 negative areas. (A, C) Pictures were
taken with a 50-fold magnification.
(TIF)
Figure S2 Western blotting analysis of Dkk-1 in control or
DKK-1-siRNA-transfected HT-29 cells. (A) Dkk-1 protein ex-
pression of control and TGF-b-stimulated HT-29 cells for 24
hours (50 ng/ml). (B) Dkk-1 protein expression of control- and
DKK-1-siRNA-transfected HT-29 cells.
(TIF)
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